Attorney Docket No.

SUBSTITUTE for PTO/SB/05 (08/00) Utility Patent Application Transmittal Approved for use through 10/31/2002 OMB 0651-0032 U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

## UTILITY PATENT APPLICATION TRANSMITTAL

First Inventor or Application Identifier Bakshi et al. SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS Title

20385YDA

(Only for new nonprovisional applications under 37 CFR 1.53(b))

MAILED BY

EL523911012US Express Mail Label No.

See MPEP c	APPLICATION ELEMENTS hapter 600 concerning utility patent application contents	Assistant Commissioner for Patents  ADDRESS TO: Box Patent Application Washington, DC 20231							
	Transmittal Form bmut an original, and a duplicate for fee processing	6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)							
2. <b>X</b> Spe	ecification [ Total Pages 101	a Computer Readable Form							
3. Dra	awing(s) (35 USC 113) [ Total Sheets	b. Paper Copy (identical to computer copy)							
	[ Total Pages	c. Statements verifying identity of above copies							
		ACCOMPANYING APPLICATION PARTS							
4. Oath or D	eclaration	7 Assignment papers (cover sheet & document(s)) 0 37 CFR 3.73(b) Statement Power of							
a.	Newly executed (original or copy)	8 (when there is an assignee) Attorney							
b. <b>X</b>	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 14 complete	9. Information Disclosure Statement Copies of IDS Citations							
		10. Preliminary Amendment							
	i. DELETION OF INVENTOR(S)  Signed statement attached deleting	11. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)							
	inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).	12. Certified Copy of Priority Document(s) (if foreign priority is claimed)							
5. Ap	oplication Data Sheet. See 37 CFR 1.76	13. Other:							
Prior applic For CONTINUAT part of the disclos  15. CORRI	ESPONDENCE ADDRESS	Group/Art Unit: 1625  for application, from which an oath or declaration is supplied under Box 4b, is considered a is hereby incorporated by reference.							
X Customi Label	(Insert Customer	er No. 000210 o. or Attach bar code here)							
NAME	Melvin Winokur								
ADDRESS	Merck & Co., Inc , P O. Box 2000 - Patent Dept.,	Y60-30							
CITY	Rahway	ATE NJ ZIP CODE 07065-0907							
COUNTRY	USA	LEPHONE 732-594-7234 FAX 732-594-4720							
Name	Melxin Wingkur	Registration No. (Attorney/Agent) 32,763							
Signature	1/10/91	Date 11/21/2001							
	EXPRESS N	AIL CERTIFICATE							
	DATE OF DEPOSIT November 21, 2001								
	EXPRESS MAIL NO. EL523911012US								
	I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"								
	ON THE ABOVE DATE IN AN ENVELOP FOR PATENTS, BOX PATENT, APPLICA	ADDRESSED TO ASSISTANT COMMISSIONER							

DATE

,	Ÿ				Patent Case N	<del> L</del>	<u> </u>
IN THE U	INITED STAT	TES PATE	NT AND TRA	DEM	ARK OFFICE	Ε	
Assistant Commissioner for Patents			Prior Applic	cation:	Examiner	Seaman, D.	
Washington, D.C. 20231 Art Unit						1625	
M. This is a request for image	ntinuation	X Divi					
application, under 37 C.F.R. 1.53(b), of pen	ding application	Serial No. 09	9/585,111		filed on		
une 1, 2000 (DATE)	of <u>Ba</u>	akshi et al.		(INVEN	TOR)		
or SUBSTITUTED PIPERIDINES AS ME	I ANOCORTIN	A RECEPTO		(2.,,21.	,		
or SUBSTITUTED PIPERIDINES AS ME	LANOCORTIN*	(TITLE O	F INVENTION)				
. The enclosed comprises a copy of prior ap	plication Serial N	No. <u>09/585,</u>	111		,	as filed on	
June 1, 2000 . The entir	e disclosure of th	is prior appli	cation is hereby	incorp	orated by referen	ice.	
. The filing fee is calculated below:							
CLAIMS AS FILED IN THE PR	IOR APPLICA	TION, LESS	ANY CLAIMS	CAN	CELED BY AM	ENDMENT BE	LOW
FOR	NUMBER FILED		NUMBER EXTRA		RATE	FEE	
Total Claims	38	- 20	T	x	\$18	\$324	
Independent Claims	10	- 3	7	х	\$84	\$588	
Multiple Dependent Claims					\$280	¢740	
Basic Fee (minimum amount required)  * Add this fee if application contains any multiple dependent claims, regardless of number.						\$740 \$1,652	Total Fee
Add this fee if application contains any must.  The Assistant Commissioner is hereby at					1		
Preliminary amendment enclosed Information Disclosure Statement Transfer the drawings from the application. A duplicate copy of New formal drawings are enclosed Priority of application Serial Notin	nt/PTO-1449 enc prior application of this sheet is en- ed.	to this appli closed for fil	ing in the prior a	applica	ition file.		; date accorded t
(COUNTRY)  The certified copy of the priority  filed	application has				l No		,
10. The prior application is assigned	i to Merck & C	o., Inc.					
11. The undersigned attorney or ago						/	
a. Nower in the prior ap		inally filed.			. ه	1/1	
b. Associate power, cop		*		Re	espectfully,	<u> </u>	_
EXPRESS MAIL CE					[[] io /	4/	<u> </u>
DATE OF DEPOSIT November 21, 200					y: Melvin Wino		
EXPRESS MAIL NO. EL523911012US					for Applicant(s) istration No. 32,763		
		IS REING			_	594- <u>7234</u>	
I HEREBY CERTIFY THAT THIS CORE DEPOSITED WITH THE UNITED STAT					•	k & Co., Inc.	

Date: November 21, 2001

IN DUPLICATE

Patent Department

P.O. Box 2000 - RY60-30 Rahway, N.J. 07065-0907

Enclosure

DATE

EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE

DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231/

MAILED BY